Trials / Completed
CompletedNCT03486899
A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis
A Phase 2B Randomized Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 197 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a study of experimental medication BMS-986036 given to adults with Nonalcoholic Steatohepatitis (NASH; the buildup of fat and inflammation in the liver that is not caused by alcohol) and stage 3 liver fibrosis (severe fibrosis).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986036 | Specified dose on specified days. |
| OTHER | Placebo | Specified dose on specified days. |
Timeline
- Start date
- 2018-06-19
- Primary completion
- 2020-09-14
- Completion
- 2021-08-17
- First posted
- 2018-04-03
- Last updated
- 2022-09-09
- Results posted
- 2022-09-09
Locations
89 sites across 2 countries: United States, Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03486899. Inclusion in this directory is not an endorsement.